Sorry, you need to enable JavaScript to visit this website.

Functional analysis of gut microbiota and immunoinflammation in children with autism spectrum disorders

TitleFunctional analysis of gut microbiota and immunoinflammation in children with autism spectrum disorders
Publication TypeArticolo su Rivista peer-reviewed
Year of Publication2019
AuthorsCarissimi, C., Laudadio I., Palone Francesca, Fulci V., Cesi Vincenzo, Cardona F., Alfonsi C., Cucchiara S., Isoldi S., and Stronati L.
JournalDigestive and Liver Disease
Volume51
Pagination1366-1374
ISSN15908658
Keywordsalarmin, article, autism, Autism Spectrum Disorder, bacterium lipopolysaccharide, biological marker, blood, case control study, Case-Control Studies, catabolism, Child, child development, clinical article, comorbidity, controlled study, cytokine, Cytokines, disease association, disease severity, enzyme linked immunosorbent assay, Escherichia coli, feces, feces analysis, Female, gamma interferon, gastrointestinal disease, Gastrointestinal Diseases, Gastrointestinal Microbiome, gastrointestinal symptom, glutathione, glutathione disulfide, high mobility group B1 protein, human, Humans, hydrocinnamic acid, immunology, inflammation, interleukin 10, interleukin 1beta, interleukin 8, intestine flora, isolation and purification, male, metabolism, metagenomics, Microbial diversity, microbiology, neurotensin, nonhuman, pathophysiology, Phenylpropionates, phenylpropionic acid derivative, Preschool, preschool child, priority journal, propionic acid, sortilin, sortilin1, transforming growth factor beta, Tumor Necrosis Factor, unclassified drug, Western blotting
Abstract

Background and Aims: Recent evidence implicates gut microbiota (GM) and immune alterations in autism spectrum disorders (ASD). We assess GM profile and peripheral levels of immunological, neuronal and bacterial molecules in ASD children and controls. Alarmin HMGB1 was explored as a non-invasive biomarker to monitor gastrointestinal (GI) symptoms. Methods: Thirty ASD children and 14 controls entered into the study. GM metagenomic analysis was performed for 16 ASD patients and 7 controls. GM functional profile was assessed by GO term analysis. Blood levels of IL-1β, TNFα, TGFβ, IL-10, INFγ, IL-8, lipopolysaccharide, Neurotensin, Sortilin1 and GSSG/GSH ratio were analyzed in all subjects by ELISA. Fecal HMGB1 was analyzed by Western blot. Results: We observed a significant decrease in bacterial diversity. Furthermore, 82 GO terms underrepresented in ASD. Four of them pointed at 3,3 phenylpropionate catabolism and were imputable to Escherichia coli (E. coli) group. Serum levels of TNFα, TGFβ, NT, and SORT-1 increased in ASD patients. Fecal levels of HMGB1 correlated with GI sign severity in ASD children. Conclusions: We suggest that a decrease of E. coli might affect the propionate catabolism in ASD. We report occurrence of peripheral inflammation in ASD children. We propose fecal HMGB1 as a non-invasive biomarker to detect GI symptoms. © 2019 Editrice Gastroenterologica Italiana S.r.l.

Notes

cited By 17

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85068930192&doi=10.1016%2fj.dld.2019.06.006&partnerID=40&md5=69dede15324964c68e3c1af43a481f6a
DOI10.1016/j.dld.2019.06.006
Citation KeyCarissimi20191366